Fig. 1From: Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLCWorkflow and PTPR alterations in NSCLC patients treated with ICIs. a Workflow of this study. b PTPR mutations landscape of multiple cohortsBack to article page